United Therapeutics (NASDAQ:UTHR) CFO Sells $5,513,815.56 in Stock

Posted by Defense World Staff on Apr 27th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 9,636 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $572.21, for a total value of $5,513,815.56. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,801,035.96. This represents a 33.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

James Edgemond also recently made the following trade(s):

On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total value of $209,609.40.
On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total value of $5,778,600.00.
On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total value of $5,771,800.00.
On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total value of $5,748,800.00.
On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total value of $5,778,900.00.
On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00.
On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $561.50, for a total value of $5,615,000.00.
On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $593.17, for a total value of $5,931,700.00.
On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total value of $5,359,000.00.
On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Stock Performance

UTHR opened at $567.16 on Monday. The firm has a market cap of $24.86 billion, a P/E ratio of 20.33, a price-to-earnings-growth ratio of 1.61 and a beta of 0.75. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89. The business’s fifty day moving average is $536.51 and its 200-day moving average is $494.61.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm posted $6.19 EPS. On average, research analysts predict that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on UTHR. Royal Bank Of Canada upped their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Bank of America upped their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. UBS Group upped their price objective on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Morgan Stanley upped their price objective on United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $601.50.

Check Out Our Latest Analysis on United Therapeutics

Hedge Funds Weigh In On United Therapeutics

Large investors have recently bought and sold shares of the company. Torren Management LLC bought a new position in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management raised its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter valued at about $31,000. Wilmington Savings Fund Society FSB raised its position in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in United Therapeutics in the fourth quarter valued at about $48,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.